Experts raise questions about routine use of surrogate endpoints for drug approvals

A growing number of drugs are being approved on the basis of indirect (‘surrogate’) measures that do not always reliably predict outcomes that matter most to patients, such as living longer or feeling better.

Generated by Feedzy